Cash, cash equivalents and investments in marketable securities were $167.9M as of June 30, compared with $127.1M as of June 30, 2024. “We have made substantial progress this year across our two indications for ersodetug in both congenital and tumor hyperinsulinism,” said Nevan Charles Elam, CEO and founder of Rezolute (RZLT). “We believe that FDA alignment on a streamlined Phase 3 trial in tumor hyperinsulinism is further recognition of ersodetug’s broad applicability across multiple forms of hyperinsulinism and highlights both the urgent need and the transformative potential of our therapy for patients and families living with this condition. We remain on track to report topline results from the sunRIZE trial in December and look forward to progressing towards potential commercialization.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute, Inc. (RZLT) Q4 Earnings Cheat Sheet
- Rezolute’s Promising Future: FDA Approval and Strategic Valuation Drive Buy Rating
- Rezolute’s Ersodetug Gains Momentum with FDA Support and Increased Success Probability, Raising Price Target
- Rezolute’s Ersodetug Gains Momentum with FDA Streamlined Phase 3 Design and Promising Efficacy in Tumor-Induced Hyperinsulinism
- Rezolute announces alignment with FDA on design for Phase 3 trial of ersodetug